Clinical Trial Update: Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC [Phase 2]

View source ↗

Summary

Taletrectinib is being studied in a Phase 2 global trial for ROS1-positive non-small cell lung cancer, with the study currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taletrectinib (taletrectinib)

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING